DNTH · Dianthus Therapeutics, Inc.

Dianthus Therapeutics’ Q1 2026 results reflect a period of strategic acceleration across both clinical and financial dimensions. Net loss widened to $40.8 million (vs. $29.5 million YoY), driven primarily by a $7.5 million increase in R&D expenses — attributed to higher clinical trial costs and expanded headcount supporting the advancing claseprubart program, particularly CAPTIVATE (CIDP), MoMeNtum (MMN), and the upcoming Phase 3 EMERGE trial in gMG. G&A expenses rose $5.2 million year-over-year, also due to increased personnel. Notably, the company strengthened its balance sheet significantly: $719 million in gross proceeds from a March 2026 public offering brought total cash, cash equivalents, and investments to $1.2 billion as of March 31, 2026 — explicitly stated to provide runway into 2030. This capital position insulates the company from near-term financing risk and enables continued investment in parallel late-stage programs. Clinically, the early GO decision in CAPTIVATE Part A — achieved with fewer than 40 participants based on 20 confirmed responders — signals strong preliminary efficacy and safety for claseprubart in CIDP, reinforcing confidence in its mechanism and supporting rapid progression to Part B. The FDA’s Orphan Drug Designation for Myasthenia Gravis and alignment on protocol simplifications (e.g., removal of ANA screening) further de-risk the gMG development path. Concurrently, DNTH212’s prioritization of SjD, SLE, and DM lays the foundation for a differentiated rheumatology franchise, with Phase 1 healthy volunteer data expected in 2H’26. Management commentary underscores a deliberate dual-franchise strategy — neuromuscular (claseprubart) and rheumatology (DNTH212) — targeting high-unmet-need autoimmune diseases through complementary, clinically validated mechanisms. No forward-looking financial guidance beyond cash runway was provided.